IL17A and rheumatoid arthritis: Galactoxylomannan (GalXM) acts on CD45RO T cells in RA to inhibit the interaction of CD45 phosphatase with T cells, the production of IL-17A, and the activation of STAT3 and caspase-3 to promote apoptosis of memory T cells (60).